Literature DB >> 17464555

Sequence analysis of TNFRSF13b, encoding TACI, in patients with systemic lupus erythematosus.

Ulrich Salzer1, Jennifer Birmelin, Chiara Bacchelli, Torsten Witte, Ulrike Buchegger-Podbielski, Sylvie Buckridge, Rita Rzepka, H Bobby Gaspar, Adrian J Thrasher, Reinhold E Schmidt, Inga Melchers, Bodo Grimbacher.   

Abstract

B cell activating factor belonging to the TNF family (BAFF) and a proliferation inducing ligand (APRIL), and their receptors BAFF receptor (BAFFR), B cell maturation antigen (BCMA), and transmembrane activator and CAML interactor (TACI) are involved in the regulation of B cell homeostasis and differentiation. BAFF overexpression leads to systemic lupus erythematosus (SLE) in mice and elevated BAFF levels have been observed in human SLE and mouse models for SLE. Furthermore, genetic inactivation of TACI in mice results in a SLE-like phenotype. Based on our recent finding that TACI is mutated in patients with common variable immunodeficiency, of whom more than 30% suffer from autoimmune conditions, we analyzed TACI in humans with SLE. Sequence analysis of TNFRSF13b/TACI in 119 unrelated SLE patients revealed four variants: R20C in exon 1, R72H in exon 3, the silent variation c.327 G > A in exon 3, and A181E in exon 4. No significant association with any of these variants was found, when compared to the frequencies of the variants in a healthy control cohort. Furthermore, the mutated alleles R20C and R72H did not segregate with the SLE phenotype in familial cases of SLE. Thus, our evaluation of the coding region of TNFRSF13b/TACI did not reveal any deleterious or disease-associated mutations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17464555     DOI: 10.1007/s10875-007-9094-y

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.542


  20 in total

1.  TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease.

Authors:  J A Gross; J Johnston; S Mudri; R Enselman; S R Dillon; K Madden; W Xu; J Parrish-Novak; D Foster; C Lofton-Day; M Moore; A Littau; A Grossman; H Haugen; K Foley; H Blumberg; K Harrison; W Kindsvogel; C H Clegg
Journal:  Nature       Date:  2000-04-27       Impact factor: 49.962

2.  Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans.

Authors:  U Salzer; H M Chapel; A D B Webster; Q Pan-Hammarström; A Schmitt-Graeff; M Schlesier; H H Peter; J K Rockstroh; P Schneider; A A Schäffer; L Hammarström; B Grimbacher
Journal:  Nat Genet       Date:  2005-07-10       Impact factor: 38.330

3.  Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome.

Authors:  Joanna Groom; Susan L Kalled; Anne H Cutler; Carl Olson; Stephen A Woodcock; Pascal Schneider; Jurg Tschopp; Teresa G Cachero; Marcel Batten; Julie Wheway; Davide Mauri; Dana Cavill; Tom P Gordon; Charles R Mackay; Fabienne Mackay
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

Review 4.  BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists.

Authors:  William Stohl
Journal:  Curr Dir Autoimmun       Date:  2005

5.  Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor.

Authors:  Dhaya Seshasayee; Patricia Valdez; Minhong Yan; Vishva M Dixit; Daniel Tumas; Iqbal S Grewal
Journal:  Immunity       Date:  2003-02       Impact factor: 31.745

6.  BLyS and APRIL in rheumatoid arthritis.

Authors:  Thorsten M Seyler; Yong W Park; Seisuke Takemura; Richard J Bram; Paul J Kurtin; Jörg J Goronzy; Cornelia M Weyand
Journal:  J Clin Invest       Date:  2005-10-20       Impact factor: 14.808

7.  Search on chromosome 17 centromere reveals TNFRSF13B as a susceptibility gene for intracranial aneurysm: a preliminary study.

Authors:  Kayoko Inoue; Youhei Mineharu; Sumiko Inoue; Shigeki Yamada; Fumihiko Matsuda; Kazuhiko Nozaki; Katsunobu Takenaka; Nobuo Hashimoto; Akio Koizumi
Journal:  Circulation       Date:  2006-04-17       Impact factor: 29.690

8.  Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus.

Authors:  W Stohl; S Metyas; S-M Tan; G S Cheema; B Oamar; V Roschke; Y Wu; K P Baker; D M Hilbert
Journal:  Ann Rheum Dis       Date:  2004-09       Impact factor: 19.103

9.  Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding.

Authors:  Sarah G Hymowitz; Darshana R Patel; Heidi J A Wallweber; Steven Runyon; Minhong Yan; Jianping Yin; Stephanie K Shriver; Nathaniel C Gordon; Borlan Pan; Nicholas J Skelton; Robert F Kelley; Melissa A Starovasnik
Journal:  J Biol Chem       Date:  2004-11-12       Impact factor: 5.157

10.  Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations.

Authors:  F Mackay; S A Woodcock; P Lawton; C Ambrose; M Baetscher; P Schneider; J Tschopp; J L Browning
Journal:  J Exp Med       Date:  1999-12-06       Impact factor: 14.307

View more
  6 in total

1.  Clinical variability of family members with the C104R mutation in transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI).

Authors:  Wikke Koopmans; See-Tarn Woon; Anna E S Brooks; P Rod Dunbar; Peter Browett; Rohan Ameratunga
Journal:  J Clin Immunol       Date:  2012-09-15       Impact factor: 8.317

2.  A custom 148 gene-based resequencing chip and the SNP explorer software: new tools to study antibody deficiency.

Authors:  Hong-Ying Wang; Vivek Gopalan; Ivona Aksentijevich; Meredith Yeager; Chi Adrian Ma; Yasmin Ali Mohamoud; Mariam Quinones; Casey Matthews; Joseph Boland; Julie E Niemela; Troy R Torgerson; Silvia Giliani; Gulbu Uzel; Jordan S Orange; Ralph Shapiro; Luigi Notarangelo; Hans D Ochs; Thomas Fleisher; Daniel Kastner; Stephen J Chanock; Ashish Jain
Journal:  Hum Mutat       Date:  2010-09       Impact factor: 4.878

3.  Protein and functional isoform levels and genetic variants of the BAFF and APRIL pathway components in systemic lupus erythematosus.

Authors:  Pilar Ortiz-Aljaro; Marco Antonio Montes-Cano; José-Raúl García-Lozano; Virginia Aquino; Rosario Carmona; Javier Perez-Florido; Francisco José García-Hernández; Joaquín Dopazo; María Francisca González-Escribano
Journal:  Sci Rep       Date:  2022-07-02       Impact factor: 4.996

4.  Heterozygous alterations of TNFRSF13B/TACI in tonsillar hypertrophy and sarcoidosis.

Authors:  Matthaios Speletas; Ulrich Salzer; Zoe Florou; Efthimia Petinaki; Zoe Daniil; Fotini Bardaka; Konstantinos I Gourgoulianis; Charalampos Skoulakis; Anastasios E Germenis
Journal:  Clin Dev Immunol       Date:  2013-07-15

5.  TACI Mutations in Primary Antibody Deficiencies: A Nationwide Study in Greece.

Authors:  Ioannis Kakkas; Gerasimina Tsinti; Fani Kalala; Evangelia Farmaki; Alexandra Kourakli; Androniki Kapousouzi; Maria Dimou; Vassiliki Kalaitzidou; Eirini Sevdali; Athanasia-Marina Peristeri; Georgia Tsiouma; Peristera Patiou; Eleni Papadimitriou; Theodoros P Vassilakopoulos; Panayiotis Panayiotidis; Anna Kioumi; Argiris Symeonidis; Matthaios Speletas
Journal:  Medicina (Kaunas)       Date:  2021-08-16       Impact factor: 2.430

6.  Relevance of biallelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TNFRSF13B variants in antibody deficiency syndromes.

Authors:  Ulrich Salzer; Chiara Bacchelli; Sylvie Buckridge; Qiang Pan-Hammarström; Stephanie Jennings; Vassilis Lougaris; Astrid Bergbreiter; Tina Hagena; Jennifer Birmelin; Alessandro Plebani; A David B Webster; Hans-Hartmut Peter; Daniel Suez; Helen Chapel; Andrew McLean-Tooke; Gavin P Spickett; Stephanie Anover-Sombke; Hans D Ochs; Simon Urschel; Bernd H Belohradsky; Sanja Ugrinovic; Dinakantha S Kumararatne; Tatiana C Lawrence; Are M Holm; Jose L Franco; Ilka Schulze; Pascal Schneider; E Michael Gertz; Alejandro A Schäffer; Lennart Hammarström; Adrian J Thrasher; H Bobby Gaspar; Bodo Grimbacher
Journal:  Blood       Date:  2008-11-03       Impact factor: 22.113

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.